A new strategy for treating psoriasis

Dexamethasone and other steroids used for treating psoriatic skin inflammation probably act in part by inducing I-kB, thus preventing NF-kB from reaching the nucleus and trans-activating its many target genes, including those involved in T cell-dependent inflammation. Zollner and colleagues now propose a different means to this same end: Since the proteasome is responsible for the regulated turnover of I-kB, proteasome inhibitors might also alleviate psoriasis by blocking NF-kB activation. Indeed, such inhibitors have already been used successfully in animal models of rheumatoid arthritis and multiple sclerosis, conditions that (like psoriasis) are thought to result from T cell exposure to bacterial antigens. Working with human psoriatic skin tissue engrafted onto mice, Zollner et al. confirm that a known bacterial superantigen can provoke psoriatic lesions. They find that proteasome inhibition prevents NF-kB activation in cultured T cells and that it blocks expression of adhesive surface molecules required for T cell homing. In engrafted mice, the inhibitor prevents psoriasis as efficiently as dexamethasone does. These different agents, which can each increase I-kB levels, presumably both silence NF-kB target genes in vivo. In addition, however, proteasome inhibitors might exert other beneficial effects, since they undoubtedly stabilizes a variety of short-lived proteins, some of which could block disease progression by other mechanisms.


Contact: John Ashkenas
Journal of Clinical Investigation

Page: 1

Related biology news :

1. A novel, safer strategy for regulating gene expression
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. European common frog found to use novel mating strategy
4. Promising hospital anti-infection strategy probably wont work, study shows
5. Parasitic cowbirds thrive with a less ruthless strategy than cuckoos
6. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys
7. UK Government proposes long-term strategy for science
8. Scientists at Scripps Research describe new strategy for the synthesis of glycoproteins
9. International HapMap Consortium publishes scientific strategy
10. HPV testing could be future strategy for primary screening for cervical cancer
11. Scientists develop a novel strategy to help prevent transplant rejection

Post Your Comments:

(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
(Date:6/23/2020)... ... , ... In its June 22 online post, business and technology news platform ... Ph.D., founder and director of stem cell biotechnology company Asymmetrex . Superb Crew ... starting July 5 it would begin offering free tissue stem cell counting ...
(Date:6/13/2020)... ... June 11, 2020 , ... Bode Technology (Bode), ... forensic genealogy team. Bode’s Forensic Genealogy Service (FGS) continues to deliver ... analysis methods. The team has added experienced genealogists, each having over a decade ...
Breaking Biology News(10 mins):
(Date:6/28/2020)... ROCKY HILL, Conn. (PRWEB) , ... June 25, ... ... systems company formed to advance photodynamic therapy for treating cancer, today announced the ... Buffalo, New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights ...
(Date:6/23/2020)... ... , ... Kerafast Inc. , developers of an online ... of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, developed by ... entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) containment. , ...
(Date:6/23/2020)... ... 2020 , ... Regen Suppliers, the one stop shop for ... get the fourth unit free with no limit on the amniotic derived exosomes. ... have been a game changer for regenerative therapies. The products are manufactured at ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... therapies, today announced that it has filed an Investigational New Drug application (IND) ... clinical trial of its lead drug candidate NBTX-001 in patients with panic disorder ...
Breaking Biology Technology:
Cached News: